The Global Clinical Trial Imaging Market is expected to reach US$ 2,480.32 million by 2028, up from US$ 1,610.70 million in 2022, expanding at a CAGR of 7.6% during the forecast period 2023–2028. Market growth is being driven by the increasing number of clinical trials, rising pharmaceutical and biotechnology research and development activities, growing use of imaging endpoints in multicenter trials, and the expanding role of contract research organizations (CROs) in clinical research.
What is driving the market?
The increasing use of medical imaging in clinical research and the rising number of clinical trials are major factors driving the global clinical trial imaging market. Clinical trial imaging provides important information for evaluating treatment efficacy, monitoring safety, assessing disease progression, and supporting regulatory submissions. Imaging can also provide insights into the mechanism of action and effects of investigational therapies, making it an important component of modern drug development.
The growing number of clinical trials conducted by pharmaceutical and biotechnology companies is creating greater demand for specialized imaging services and technologies. ClinicalTrials.gov data cited by The Insight Partners indicate that registered studies increased from approximately 52,000 in 2020 to approximately 58,000 in 2023, while thousands of clinical trials are also authorized annually in the European Union. The increasing complexity of clinical research is encouraging sponsors to outsource trial activities to CROs with specialized expertise.
Download Sample PDF: https://www.theinsightpartners.com/sample/TIPHE100001201
Which region leads?
North America held the largest share of the global clinical trial imaging market, accounting for 40.8% in 2022. The region benefits from a well-established clinical research ecosystem, significant pharmaceutical and biotechnology research and development investments, advanced healthcare infrastructure, and a high concentration of CROs and clinical research service providers.
The United States represents a particularly important market within North America. The country has a large clinical research base, established medical infrastructure, favorable regulatory conditions, and extensive pharmaceutical research activities. The Insight Partners estimates that the US clinical trial imaging market is projected to grow at a CAGR of approximately 8% during the forecast period.
Europe also represents a significant market due to its established clinical research infrastructure and substantial pharmaceutical industry. Increasing clinical trial activity and the adoption of standardized imaging protocols are supporting demand for imaging services and technologies across the region.
Asia Pacific is expected to witness strong growth, with the market projected to register an 8.2% CAGR during the forecast period. Expanding clinical research activities, growing pharmaceutical and biotechnology industries, increasing healthcare investment, and the development of clinical research infrastructure across countries such as China, India, Japan, and Australia are creating new opportunities for clinical trial imaging providers.
Which segment leads?
Tomography represented the largest modality segment of the clinical trial imaging market, accounting for 38.1% of the market in 2022. Tomography, particularly computed tomography (CT), plays an important role in clinical research by generating cross-sectional images of bones, blood vessels, and soft tissues. CT imaging is extensively used in oncology research and drug development, where repeated imaging is required to monitor disease progression and treatment response.
The market is segmented by modality into tomography, magnetic resonance imaging (MRI), ultrasound, positron emission tomography (PET), X-ray, echocardiography, and others. Each modality provides distinct imaging capabilities that can support different therapeutic areas and clinical trial endpoints.
By offering, the market includes operational imaging services, imaging software, read analysis services, trial design and consulting services, and others. Operational imaging services represented an important portion of the market, while imaging software is expected to experience strong growth, with The Insight Partners projecting a CAGR of 8.2% during the forecast period.
Clinical trial imaging software is becoming increasingly important as sponsors and CROs seek to manage large volumes of images, standardize workflows, improve image traceability, and support consistent image interpretation. Advanced platforms can also help coordinate imaging activities across multiple trial sites and readers.
By end user, the market includes contract research organizations, pharmaceutical and biotechnology companies, academic and research institutes, and others. Contract research organizations represented the largest end-user segment, accounting for 45.4% of the market in 2022.
Which companies are prominent?
The global clinical trial imaging market includes specialized imaging providers, CROs, clinical research technology companies, and healthcare technology organizations competing through imaging services, software, image analysis, clinical trial management, and consulting solutions. Prominent participants include:
- eResearch Technology Inc
- Calyx Inc
- ICON PLC
- VIDA Diagnostics Inc
- WCG Clinical Inc
- BioTelemetry Inc
- Medical Metrics Inc
- Medpace Holdings Inc
- Radiant Sage LLC
- IXICO plc
These companies are involved in providing clinical trial imaging capabilities and related research services. Competition is influenced by imaging expertise, technology platforms, data management capabilities, global trial infrastructure, regulatory knowledge, and the ability to provide standardized and efficient imaging workflows.
The competitive landscape is also being shaped by organic and inorganic strategies, including product launches, service expansion, partnerships, collaborations, and technology development. As sponsors increasingly outsource clinical research activities, providers with integrated imaging and clinical trial capabilities can strengthen their market position.
What is changing in 2026?
In 2026, the clinical trial imaging market is increasingly shifting toward digital imaging workflows, centralized image management, advanced imaging software, and technology-enabled image analysis. The growing complexity and volume of imaging data generated during multicenter trials are increasing the need for platforms that can coordinate image acquisition, transfer, storage, analysis, and interpretation.
Digital clinical trial imaging platforms are helping sponsors and CROs improve visibility across imaging activities and support more consistent data management. Cloud-based technologies can also facilitate collaboration among researchers, imaging specialists, and clinical trial teams across geographically distributed locations.
Artificial intelligence and advanced image analysis are creating additional opportunities. AI-enabled technologies can assist with image interpretation, quantitative analysis, lesion assessment, and biomarker development. These capabilities may help reduce variability in image assessment while supporting more efficient clinical trial workflows.
Purchase a Copy of this report: https://www.theinsightpartners.com/buy/TIPHE100001201
What are the major investment opportunities?
Investment opportunities in the clinical trial imaging market are emerging across imaging software, centralized image management, AI-enabled image analysis, operational imaging services, imaging biomarkers, and specialized CRO capabilities. As pharmaceutical and biotechnology companies increase investments in drug development, demand for efficient and scalable imaging infrastructure is expected to create opportunities for technology providers and specialized service companies.
Imaging software represents an attractive opportunity because clinical trials increasingly require sophisticated systems to manage large volumes of medical images and associated clinical data. Software platforms that support image standardization, secure data exchange, reader management, quality control, and workflow monitoring can provide value to clinical trial sponsors and CROs.
The expansion of imaging CROs is another important opportunity. Specialized CROs can help pharmaceutical companies manage the technical and operational challenges associated with clinical trial imaging, including site qualification, protocol standardization, image acquisition, reader training, image interpretation, and data management.
Also Available in: Korean | German | Japanese | French | Chinese | Italian | Spanish
Related Reports:
Mammography Detectors Market Size, Share & Demand by 2034
Mass Spectrometry Market Size, Share & Forecast by 2034
About Us
The Insight Partners is a one-stop provider of actionable industry research and intelligence. We help our clients get solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Food and Beverages, Consumer Goods, and Chemicals and Materials.
Contact US
Contact Person: Ankit Mathur
Phone: +1-646-491-9876
E-mail : sales@theinsightpartners.com
